From Yahoo Finance: 2025-04-14 10:29:00

A recent article listed 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. Merck & Co. (NYSE:MRK) is one of these stocks, with a Forward P/E Ratio of 9.02 and 91 Hedge Fund Holders. The company operates in the Pharmaceutical and Animal Health sectors, with Keytruda sales reaching $29.5 billion in 2024.

Jack Caffrey of JPMorgan Asset Management discussed market trends on CNBC’s ‘Squawk Box’, emphasizing diversified portfolios and the importance of ‘time in the market’. He highlighted the difficulty of predicting market behavior and the recent volatility in the market. Caffrey also mentioned the shift from monetary to fiscal stimulus measures in Europe.

Merck & Co. (NYSE:MRK) has secured regulatory approvals for its Keytruda-based regimens and plans to seek approval for other treatments by mid-2025. The company’s Keytruda sales saw significant growth in 2024, driven by global demand for cancer treatments. DBS analyst Nico Chen maintained a Buy rating for the company with a $100 price target.

According to GreensKeeper Asset Management, Merck & Co., Inc. (NYSE:MRK) faced challenges with its HPV vaccine, GARDASIL 9, due to inventory buildup in China. Despite this, the company’s Keytruda cancer treatment continues to grow steadily. MRK ranks 10th on the list of cheap NYSE stocks to invest in according to hedge funds.

Read more: Is Merck & Co. (NYSE:MRK) a Cheap NYSE Stock to Invest in According to Hedge Funds?